News
VCYT
--
0.00%
--
Money Supply Is Up 26%, Inflation Coming? Cathie Woods Bitcoin Comments and Stock Picks
In this article we talked about Cathie Woods’ recent comments about money supply, inflation, interest rates, bitcoin and present Woods’ top 10 small-cap stock picks. Click to skip ahead our lengthy discussion and see Cathie Woods’ Top 5 Small-Cap Stock Pic...
Insider Monkey · 14h ago
Insider Trends: Veracyte Insider Reports Option Conversion Extending 90-Day Buying Trend
MT Newswires · 3d ago
Myasthenia Gravis Diagnosis and Treatment Market by Type, Component, End-user, Application, and Region – Global Forecast to 2027
Jan 21, 2021 (Heraldkeepers) -- Global Myasthenia Gravis Diagnosis and Treatment Industry Myasthenia gravis is a chronic autoimmune disorder in which the...
Heraldkeepers · 3d ago
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
Business Wire · 01/06 19:00
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021, at 4:15 p.m. ...
BusinessWire · 01/06 16:00
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
GlobeNewswire · 12/23/2020 13:00
Veracyte and Bayer collaborate in precision oncology; shares jump +17%
Veracyte (VCYT) is up +16.8% after announcing a collaboration with Bayer (BAYZF) to advance its Afirma Xpression Atlas for targeted therapies in patients with advanced or metastatic thyroid cancer.Regardless of the results and
Seekingalpha · 12/22/2020 16:34
Veracyte (VCYT) in Focus: Stock Moves 7% Higher
Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks · 12/22/2020 13:52
Bayer, Veracyte Announce Precision Oncology Collaboration In Thyroid Cancer
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer Bayer and Veracyte (NASDAQ:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification
Benzinga · 12/22/2020 13:17
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte's Afirma Xpression Atlas (XA) to identify ...
BusinessWire · 12/22/2020 10:15
Veracyte Announces ISO 13485:2016 Certification For Its In Vitro Diagnostics Quality Management System
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System Veracyte, Inc. (NASDAQ:VCYT) today announced that the company has received ISO 13485:2016 certification for its
Benzinga · 12/21/2020 13:18
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
Veracyte received ISO 13485:2016 certification for the company's in vitro diagnostics Quality Management System.
Business Wire · 12/21/2020 13:15
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has received ISO 13485:2016 certification for its Quality Management System (QMS) for the design, development and manufacture of genomic in vitro diagnostic (IVD) tests that aid in the diagnosi...
BusinessWire · 12/21/2020 10:15
Veracyte announces new preliminary data for lung cancer tests
Veracyte (VCYT) releases the new preliminary performance data for its non-invasive nasal swab test and Percepta Genomic Atlas.Currently undergoing development, the tests are on track for launch in the second
Seekingalpha · 12/16/2020 17:45
Veracyte Announces New Preliminary Data For In-Development Lung Cancer Portfolio Tests
Data on Noninvasive Nasal Swab Test and Percepta Genomic Atlas Presented Today at Virtual Lung Cancer R&D Day Veracyte, Inc. (NASDAQ:VCYT) announced new preliminary performance data for its noninvasive nasal swab
Benzinga · 12/16/2020 17:05
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
Business Wire · 12/16/2020 17:00
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
Veracyte, Inc. (Nasdaq: VCYT) announced new preliminary performance data for its noninvasive nasal swab test for early lung cancer detection and its Percepta Genomic Atlas for informing treatment decisions at the time of diagnosis. Both tests are in develo...
BusinessWire · 12/16/2020 14:00
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Business Wire · 12/15/2020 22:59
Veracyte broadens the collaboration with JNJ in early cancer detection
Intending to speed up the development of its non-invasive nasal swab test for early lung cancer detection ahead of a potential launch in 2021, Veracyte, Inc. (VCYT) has expanded the
Seekingalpha · 12/15/2020 14:49
Veracyte Announces Expansion Of Collaboration With The Lung Cancer Initiative At Johnson & Johnson
Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests Veracyte, Inc. (NASDAQ:VCYT) today announced it has expanded its long-term strategic
Benzinga · 12/15/2020 13:16
Webull provides a variety of real-time VCYT stock news. You can receive the latest news about Veracyte through multiple platforms. This information may help you make smarter investment decisions.
About VCYT
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
More